СОВРЕМЕННЫЕ ТЕНДЕНЦИИ ИСПОЛЬЗОВАНИЯ АНТИКОНВУЛЬСАНТОВ В ПСИХИАТРИЧЕСКОЙ ПРАКТИКЕ

Иван Александрович Демьянов; Валерия Васильевна Сурикова; Елена Юрьевна Мельник

doi:10.21638/11701/spbu11.2017.303

Авторы

Иван Александрович Демьянов Специализированная клиническая психиатрическая больница № 1, Российская Федерация, 350007, Краснодар, ул. Красная, 1 ; Кубанский государственный медицинский университет, Российская Федерация, 350063, Краснодар, ул. Седина, 4
Валерия Васильевна Сурикова Кубанский государственный медицинский университет, Российская Федерация, 350063, Краснодар, ул. Седина, 4
Елена Юрьевна Мельник Специализированная клиническая психиатрическая больница № 1, Российская Федерация, 350007, Краснодар, ул. Красная, 1

DOI:

https://doi.org/10.21638/11701/spbu11.2017.303

Аннотация

В обзорной статье рассмотрены современные тенденции применения антиконвульсантов
в психиатрической практике, являющиеся малоизученной и редко затрагиваемой проблемой, за исключением вопросов терапии биполярного расстройства. Кратко описаны основные особенности группы препаратов. Представлены данные зарубежных исследований по основным антиконвульсантам. Рассмотрены результаты как крупных метаанализов, так и открытых исследований с малым количеством пациентов, демонстрирующие основные направления научных изысканий по данной тематике. Приведенные данные могут стать основой не только для дальнейших исследований, но и для осмотрительного и разумного применения в клинической практике, особенно в сложных, труднокурабельных случаях, требующих от врача максимально широкого кругозора и знания современных тенденций в психиатрии. Библиогр. 55 назв.

Ключевые слова:

антиконвульсанты, психофармакотерапия, психиатрия, шизофрения, расстройства пищевого поведения

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

References

Tariot P. N., Loy R., Ryan J., Porsteinsson A., Ismail S. Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv. Drug Deliv. Rev., 2002, vol. 54, no. 2, pp. 1567–1577.

Lonergan E., Cameron M., Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst. Rev., 2004, no. 2, CD003945.

Tariot P. N., Schneider L. S., Cummings J., Thomas R. G., Raman R., Jakimovich L. J., Loy R., Bartocci B., Fleisher A., Ismail M. S., Porsteinsson A., Weiner M., Jack C. R. Jr., Thal L., Aisen P. S. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry, 2011, vol. 68, no. 8, pp. 853–861

Rogawski M. A., Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.Nature Medicine, 2004, vol. 10, no. 7, pp. 685–692.

Spina E., Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord., 2004, vol. 6,no. 2, pp. 57–75.

Ettinger A. B., Argoff C. E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics, 2007, vol. 4, no. 1, pp. 75–83.

Ali I. I., Schuh L., Barkley G. L., Gates J. R. Antiepileptic drugs and reduced bone mineral density.Epilepsy Behav., 2004, vol. 5, no. 3, pp. 296–300.

Rosenblat J. D., Gregory J. M., Carvalho A. F., McIntyre R. S. Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms. Curr. Mol. Med., 2016, vol. 16, no. 2, pp. 165–178.

Williams L. J., Pasco J. A., Jackson H., Kiropoulos L., Stuart A. L., Jacka F. N., Berk M. Depression as a risk factor for fracture in women: A 10-year longitudinal study. J. Affect. Disord., 2016, vol. 192, pp. 34–40.

Hollander E., Tracy K. A., Swann A. C., Coccaro E. F., McElroy S. L., Wozniak P., Sommerville K. W.,Nemeroff C. B. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.

Neuropsychopharmacology, 2003, vol. 28, no. 6, pp. 1186–1197.

Hollander E., Swann A. C., Coccaro E. F., Jiang P., Smith T. B. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am. J. Psychiatry, 2005, vol. 162, no. 3, pp. 621–624.

Hollander E., Chaplin W., Soorya L. Wasserman S., Novotny S., Rusoff J., Feirsen N., Pepa L., Anagnostou E. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 2010, vol. 35, no. 4, pp. 990–998.

Kaufman K. R. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav., 2011, vol. 21, no. 1, pp. 1–11.

Leweke F. M., Gerth C. W., Koethe D., Faulhaber J., Klosterkotter J. Oxcarbazepine as an Adjunct for Schizophrenia. Am. J. Psychiatry, 2004, vol. 161, pp. 1130–1131.

Kapetanovic S. Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. Am. J. Psychiatry, 2007, vol. 164, no. 5, pp. 832–833.

Hosák L., Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur. Psychiatry, 2002, vol. 17, no. 7, pp. 371–378.

Dursun S. M., McIntosh D., Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia.Arch. Gen. Psychiatry, 1999, vol. 56, p. 950.

Tiihonen J., Hallikainen T., Ryynanen O. P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P.,Wahlbeck K., Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry, 2003, vol. 54, no. 11, pp. 1241–1248.

Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res., 2009, vol. 109, no. 1–3, pp. 10–14.

Vayisoğlu S., Anil Yağcıoğlu A. E., Yağcioğlu S., Karahan S., Karci O., Gürel S. C., Yazici M. K. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.Schizophr. Res., 2013, vol. 143, no. 1, pp. 207–214.

Kumar T. C., Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessivecompulsive disorder. Australian and New Zealand Journal of Psychiatry, 2000, vol. 34, pp. 527–528.

Bruno A., Mico U., Pandolfo G., Mallamace D., Abenavoli E., Di Nardo F., D’Arrigo C., Spina E.,Zoccali R. A., Muscatello M. R. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J. Psychopharmacol., 2012,vol. 26, pp. 1456–1462.

Pinto O. C., Akiskal H. S. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J. Affect. Disord. 1998, vol. 51, no. 3, pp. 333–343.

Sieberer M., Emrich H. M. Empirical evidence for the use of anticonvulsants in personality disorders. Fortschr. Neurol. Psychiatr., 2009, vol. 77, no. 3, pp. 133–138.

Stoffers J., Völlm B. A., Rücker G., Timmer A., Huband N., Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst. Rev., 2010, no. 6, CD005653.

Phillips K. A., Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder.CNS Spectr., 2009, vol. 14, no. 5, pp. 252–260.

Simon N. M., Worthington J. J., Doyle A. C., Hoge E. A., Kinrys G., Fischmann D., Link N., Pollack M. H. An open-label study of levetiracetam for the treatment of social anxiety disorder. Clin. Psychiatry,2004, vol. 65, no. 9, pp. 1219–1222.

Weiner M., Womack K., Martin-Cook K., Svetlik D. A., Hynan L. S. Levetiracetam for agitated Alzheimer’s disease patients. Int. Psychogeriatr., 2005, vol. 17, no. 2, pp. 327–328.

Kyomen H. H., Whitfield T. H., Baldessarini R. J. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer’s type. Journal of Clinical Psychopharmacology, 2007,vol. 27, no. 4, pp. 408–410.

Rodríguez-Toledo S., Trebbau-López H., Reyes-Molón L., del Río-Vega J. Levetiracetam and psychosis.Actas Esp. Psiquiatr., 2012, vol. 40, no. 1, p. 49.

Zaki S. A., Gupta S. Levetiracetam-induced acute psychosisin a child. Indian J. Pharmacol., 2014,vol. 46, no. 3, pp. 341–342.

Kumar N., Swaroop H. S., Chakraborty A., Chandran S. Levetiracetam induced acute reversible psychosis in a patient with uncontrolled seizures. Indian J. Pharmacol., 2014, vol. 46, no. 5, pp. 560–561.

Gadde K. M., Franciscy D. M., Wagner H. R. 2nd, Krishnan K. R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA, 2003, vol. 289, no. 14, pp. 1820–1825.

Gadde K. M., Kopping M. F., Wagner H. R. 2nd, Yonish G. M., Allison D. B., Bray G. A. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch. Intern. Med., 2012, vol. 172,no. 20, pp. 1557–1564.

McElroy S. L., Winstanley E., Mori N., Martens B., McCoy J., Moeller D., Guerdjikova A. I.,Keck P. E. Jr. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J. Clin. Psychopharmacol., 2012, vol. 32, no. 2, pp. 165–172.

Correll C. U., Maayan L., Kane J., Martens B., McCoy J., Moeller D., Guerdjikova A. I., Keck P. E. Jr. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: Results from a meta-analysis of randomized controlled trials.J. Clin. Psychiatry, 2016, vol. 77, no. 6, pp. 746–756.

Khera R., Murad M. H., Chandar A. K., Dulai P. S., Wang Z., Prokop L. J., Loomba R., Camilleri M.,Singh S. Association of pharmacological Treatments for obesity with weight loss and adverse events: a systematic

review and meta-analysis. JAMA, 2016, vol. 315, no. 22, pp. 2424–2434.

Siebenhofer A., Jeitler K., Horvath K., Berghold A., Posch N., Meschik J., Semlitsch T. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst. Rev., 2016, no. 3,

CD007654.

Hedges D. W., Reimherr F. W., Hoopes S. P., Rosenthal N. R., Kamin M., Karim R., Capece J. A. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J. Clin. Psychiatry, 2003, vol. 64, no. 12, pp. 1449–1454.

Hoopes S. P., Reimherr F. W., Hedges D. W., Rosenthal N. R., Kamin M., Karim R., Capece J. A., Karvois D. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J. Clin. Psychiatry, 2003, vol. 64, no. 11, pp. 1335–1341.

McElroy S. L., Arnold L. M., Shapira N. A., Keck P. E. Jr., Rosenthal N. R., Karim M. R., Kamin M.,Hudson J. I. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized,

placebo-controlled trial.Am. J. Psychiatry, 2003, vol. 160, no. 2, pp. 255–261.

McElroy S. L., Guerdjikova A. I., Martens B., Keck P. E. Jr., Pope H. G., Hudson J. I. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs., 2009, vol. 23, no. 2, pp. 139–156.

Kim J. H., Yim S. J., Nam J. H. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr. Res., 2006,

vol. 82, no. 1, pp. 115–117.

Talaei A., Farıdhosseini F., Kazemi H., Fayyazi Bordbar M. R., Rezaei Ardani A. Effect of topiramate on drug associated weight gain of patients with schizophrenia and bipolar i disorders: A dose ranging randomized

trial. Turk Psikiyatri Derg., 2016, vol. 27, no. 2.

Narula P. K., Rehan H. S., Unni K. E., Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr.

Res., 2010, vol. 118, no. 1–3, pp. 218–223.

Evers S. S., van Vliet A., van Vugt B., Scheurink A. J., van Dijk G. A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers. Psychoneuroendocrinology, 2016, vol. 66, pp. 101–110.

Khazaal Y., Cornuz J., Bilancioni R., Zullino D. F. Topiramate for smoking cessation. Psychiatry Clin.Neurosci., 2006, vol. 60, pp. 384–388.

Reid M. S., Palamar J., Raghavan S., Flammino F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology, 2007,

vol. 192, pp. 147–158.

Lochner C., Seedat S., Niehaus D. J., Stein D. J. Topiramate in the treatment of trichotillomania: An open-label pilot study. Int. Clin. Psychopharmacol., 2006, vol. 21, pp. 255–259.

Achab S., Khazaal Y. Psychopharmacological treatment in pathological gambling: a critical review.Curr. Pharm. Des., 2011, vol. 17, no. 14, pp. 1389–1395.

Egorov A. Iu. Sovremennye podkhody k terapii igrovoi zavisimosti [Modern treatment approaches to gambling]. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova, 2014, issue 2, vol. 114, no. 5, pp. 46–52. (In Russian)

Rosenberg O., Dinur L. K., Dannon P. N. Four-year follow-up study of pharmacological treatment in pathological gamblers. Clin. Neuropharmacol., 2013, vol. 36, no. 2, pp. 42–45.

Berlin H. A., Braun A., Simeon D., Koran L. M., Potenza M. N., McElroy S. L., Fong T., Pallanti S., Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J. Biol.

Psychiatry, 2013, vol. 14, no. 2, pp. 121–128.

McElroy S. L., Arnold L. M., Shapira N. A., Keck P. E. Jr., Rosenthal N. R., Karim M. R., Kamin M., Hudson J. I. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized,

placebo-controlled trial. Am. J. Psychiatry, 2003, vol. 160, no. 2, pp. 255–261.

Yip S. W., Potenza M. N. Treatment of Gambling Disorders. Curr. Treat. Options Psychiatry, 2014,vol. 1, no. 2, pp. 189–203.